The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity.

Date publication

novembre 2017

Journal

Retrovirology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr RUFF Marc

Tous les auteurs :
Amadori C, van der Velden YU, Bonnard D, Orlov I, van Bel N, Le Rouzic E, Miralles L, Brias J, Chevreuil F, Spehner D, Chasset S, Ledoussal B, Mayr L, Moreau F, García F, Gatell J, Zamborlini A, Emiliani S, Ruff M, Klaholz BP, Moog C, Berkhout B, Plana M, Benarous R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29121950

Résumé

HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration. Recently a new class of IN inhibitors was described, the IN-LEDGF allosteric inhibitors (INLAIs). Designed to interfere with the IN-LEDGF interaction during integration, the major impact of these inhibitors was surprisingly found on virus maturation, causing a reverse transcription defect in target cells.

Mots clés

Allosteric integrase inhibitor, HIV-1, INLAI, Immunoreactivity, Integrase, LEDGF, LEDGIN

Référence

Retrovirology. 2017 Nov 9;14(1):50